N,N′-diacetylchitobiose, an inhibitor of lysozyme, reverses myocardial depression and lessens norepinephrine requirements in Escherichia coli sepsis in dogs

Shock

Volumn 29, Issue 6, 2008, Pages 681-687

  Mink, Steven N ^a,b   Kasian, Krika ^a   Jacobs, Hans ^a   Cheng, Zhao Qin ^a   Light, R Bruce ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Chitobiose; Endotoxemia; Glycoproteins; Left ventricular depression; Myocardial depressant factor; Septic shock; Stroke work

Indexed keywords

CHITOBIOSE; NORADRENALIN; AUTACOID; DISACCHARIDE; ENZYME INHIBITOR; LYSOZYME; N,N DIACETYLCHITOBIOSE; N,N-DIACETYLCHITOBIOSE; VASOCONSTRICTOR AGENT;

ANIMAL EXPERIMENT; ARTERIAL PH; ARTICLE; BACTEREMIA; CONTROLLED STUDY; DOG; ESCHERICHIA COLI; HEART DISEASE; HEMODYNAMICS; NONHUMAN; SEPSIS; STROKE; ANIMAL; CARDIOMYOPATHY; DRUG ANTAGONISM; DRUG EFFECT; ENTEROBACTER INFECTION; ENZYMOLOGY; HEART STROKE VOLUME; HUMAN; MALE; METABOLISM; PATHOPHYSIOLOGY; SEPTIC SHOCK; TIME;

ANIMALS; BACTEREMIA; CARDIOMYOPATHIES; DISACCHARIDES; DOGS; ENZYME INHIBITORS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; INFLAMMATION MEDIATORS; MALE; MURAMIDASE; NOREPINEPHRINE; SHOCK, SEPTIC; STROKE VOLUME; TIME FACTORS; VASOCONSTRICTOR AGENTS;

EID: 44449158049     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e31815816c3     Document Type: Article

References (30)

1. Parker MM, Shelhamer JH, Bacharach SL, Green MV, Natanson C, Frederick TM, Damske BA, Parrillo JE: Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 100:483-490, 1984.
2. Lefer A, Rovetto M: Influence of a myocardial depressant factor on physiologic properties of cardiac muscle. Proc Soc Exp Biol 134:269-273, 1970.
3. Lefer A, Cowgill R, Marshall F, Hall LM, Brand ED: Characterization of a myocardial depressant factor present in hemorrhagic shock. Am J Physiol 213:492-498, 1967.
4. Parrillo J, Burch C, Shelhamer J, Parker MM, Natanson C, Schueutte W: A circulating myocardial depressant substance in humans with septic shock. J Clin Invest 76:1539-1553, 1985.
5. Mink SN, Jacobs H, Bose D, Duke K, Cheng ZQ, Light RB: Lysozyme: a mediator of myocardial depression and adrenergic dysfunction in septic shock in dogs. J Mol Cell Cardiol 35:265-275, 2003.
6. Briggs RS, Perillie PE, Finch SC: Lysozyme in bone marrow and peripheral blood cells. J Histochem Cytochem 14:167-170, 1966.
7. Hansen NE, Andersen V: Lysozyme activity in human neutrophilic granulocytes. Br J Haematol 24:613-623, 1973.
8. Hansen NE, Karle H, Andersen V, Olgaard K: Lysozyme turnover in man. J Clin Invest 51:1146-1155, 1972.
9. Fleming A: On a remarkable bacteriolytic element found in tissue and secretions. Proc R Soc Lond (Biol) 93:306-307, 1922.
10. Chipman DM, Sharon N: Mechanism of lysozyme action. Science 165:454-465, 1965.
11. Rand-Meir T, Dahlquist FW, Raftery MA: Use of synthetic substrates to study binding and catalysis by lysozyme. Biochemistry 8:4206-4214, 1969.
12. Jacobs H, Mink SN, Duke K, Bose D, Cheng ZQ, Howelett S, Ferrier GR, Light RB: Characterization of membrane N-glycan binding sites of lysozyme for cardiac depression in sepsis. Intensive Care Med 31:129-137, 2005.
13. Mink SN, Bose R, Roberts DE, Jacobs H, Duke K, Bose D, Cheng ZQ, Light RB: Lysozyme binding to endocardial endothelium mediates myocardial depression by the nitric-oxide guanosine 3′,5′ monophosphate pathway in sepsis. J Mol Cell Card 30:615-625, 2005.
14. Lohmann SM, Vaandrager AB, Smolenski A, Walter U, De Jonge HR: Distinct and specific functions of cGMP-dependent protein kinases. Trends Biochem Sci 22:307-312, 1997.
15. Mink SN, Jacobs H, Duke K, Bose D, Cheng ZQ, Light RB: N,N′,N″ triacetylglucosamine, an inhibitor of lysozyme, prevents myocardial depression in E coli sepsis in dogs. Crit Care Med 32:184-193, 2004.
16. Beale RJ, Hollenberg SM, Vincent JL, Parrillo JE: Vasopressor and inotropic support in septic shock: an evidence-based review. Crit Care Med 32:S455-S465, 2004.
17. Chrusch C, Bands C, Bose D, Li X, Jacobs H, Duke K, Bautista E, Eschun G, Light RB, Mink SN: Impaired hepatic extraction and increased splanchnic production contribute to lactic acidosis in canine sepsis. Am J Respir Crit Care Med 161:517-526, 2000.
18. National Institutes of Health. Guide for the Care and Use of Laboratory Animals (NIH publication no. 85-23). Bethesda, MD: National Institutes of Health, 1996.
19. Gomez A, Wang R, Unruh H, Light RB, Bose D, Chau T, Correa E, Mink SN: Hemofiltration reverses left ventricular dysfunction during sepsis in dogs. Anesthesiology 73:671-685, 1990.
20. Flecknell P. Laboratory Animal Anaesthesia. 2nd ed. San Diego, CA: Academic Press, 1996.
21. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tamlanovich M: Early goal-directed therapy collaborative G: early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368-1377, 2001.
22. Chen A, Taguchi T, Sakai K, Matahira Y, Wang MW, Miwa I: Effect of chitobiose and chitotriose on carbon tetrachloride-induced acute hepatoxicity in rats. Biol Pharm Bull 28:1971-1973, 2005.
23. Chen A, Taguchi T, Okamtoto H, Danjo K, Sakai K, Matahira Y, Wang MW, Miwa I: Pharmacokinetics of chitobiose and chitotriose administered intravenously or orally to rats. Biol Pharm Bull 28:545-548, 2005.
24. Talent JM, Gracy RW: Pilot study of oral polymetric N-acetyl- D-glucosamine as a potential treatment for patients with osteoarthritis. Clin Ther 18:1184-1190, 1996.
25. Cooper DJ, Worthley LI: Adverse hemodynamic effects of sodium bicarbonate in metabolic acidosis. Intensive Care Med 12:285-288, 1986.
26. Williams DL, Ozment-Skelton T, Li C: Modulation of the phosphoinositide 3-kinase signalling pathway alters host response to sepsis, inflammation, and ischemia/reperfusion injury. Shock 25:432-439, 2006.
27. Minutoli L, Altavilla D, Bitto A, Polito F, Bellocco E, Lagana G, Giuliani D, Flumara T, Magazu S, Ruggeri P, et al.: The disaccharide trehalose inhibits proinflammatory phenotype activation in macrophages and prevents mortality in experimental septic shock. Shock 27:91-96, 2007.
28. Grover R, Zaccardelli D, Colice G, Guntupallli K, Watson D, Vincent JL: An open label dose escalation study of the nitric oxide synthase inhibitor, N(G) methyl-L-arginine hydrochloride (546C88) in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. Crit Care Med 27:913-922, 1999.
29. Burgess P, Appel SH, Wilson CA, Polk HC Jr: Detection of intraabdominal abscess by serum lysozyme estimation. Surgery 115:16-21, 1994.
30. Annane D, Bellissant E, Cavaillon JM: Septic shock. Lancet 365:63-78, 2005.